Covid-19 Vaccine Candidate
Premas develops novel & transformational technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates.
Akers licensed a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™.
The Premas platform has three key advantages which will set this vaccine candidate apart from industry peers.
- Premas has previously expressed more than 30 proteins of similar profile to those in the structure of Covid-19,
therefore the platform is well suited for the expression of difficult vaccine candidate proteins.
The technology platform is highly scalable with a robust process, which should represent significant cost savings compared to other similar vaccine platforms.
The current global pandemic might allow for an expedited FDA review timeline based on recent pronouncements regarding other Covid-19 vaccine and treatment candidates.
Premas successfully cloned three Coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) in the first quarter of 2020 which further differentiates our vaccine candidate.
We aim to provide the immune system with several opportunities to identify the virus; a design concept extremely important for efficacy and our future success.
We held a conference call with Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, in late March.
The transcript, which provides additional information on our philosophy and milestone timeline, can be accessed here.
Notice of Settlement – to current Akers Stockholders
Particle Immuno-Filtration Assay (PIFA®) Technology
PIFA® technology is a cutting-edge, patented immunoassay method which rapidly, easily, and accurately detects target antigens or antibodies.
How It Works
PIFA® technology is based on the selective filtration of microparticles in response to antibody/antigen binding.
Dyed microparticles coated with antigens or antibodies determine the visual signal for the results of the assay.
The presence of a corresponding antibody or antigen in the test sample results in the formation of a matrix of microparticles, which are more susceptible to filtration.
The inability of these matrixed microparticles to move through the filter, and the resulting color change in the reagent mixture,
signal positive reactivity of the test sample (e.g. the presence of target antigens or antibodies).
Key features of PIFA® technology make it advantageous for a broad array of uses:
- Accuracy rivaling or surpassing current laboratory methods
Rapid Results, typically within 1 to 5 minutes
Easy to use
Easy to dispose
PIFA® technology is currently used in:
PIFA® technology is available for licensing. To inquire about licensing or for technical inquiries, please contact us.